Efficacy of neoadjuvant endocrine therapy with CDK4/6 inhibitors in locally advanced breast cancer
The Oncologist · 05.02.2026 · 31 (3)
DOI: 10.1093/oncolo/oyag032 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 06.02.2026. Verfasst von Mengqi Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Neoadjuvant Therapy, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
Neoadjuvant treatment for hormone receptor (HR)-positive breast cancer remains limited, particularly for tumors that are insensitive to neoadjuvant chemotherapy. This study aims to compare the efficacy of neoadjuvant endocrine therapy combined with CDK4/6 inhibitors to that of traditional neoadjuvant chemotherapy. Patients and methods A total of 49 patients receiving neoadjuvant endocrine therapy plus CDK4/6 inhibitors and 210 receiving neoadjuvant chemotherapy were enrolled. Magnetic resonance imaging was performed to assess tumor responses every 2-3 cycles of treatment. Propensity score matching (PSM) was performed to balance baseline characteristics.
Results
Both before and after PSM, the objective response rate (ORR) in the endocrine therapy group was comparable to that of the traditional chemotherapy group. After matching, the ORR was 64.6% (95% CI, 49.5-77.8) in the endocrine group and 56.3% (95% CI, 41.2-70.5) in the chemotherapy group (P = .532). A higher proportion of patients in the endocrine group achieved a pathological complete or near-complete response (Miller-Payne grades 4-5, 13.5% vs 10.4%) and post-treatment Ki67 < 5%, indicating a potential long-term benefit. Patients with ≥30% regression in maximal tumor diameter after 2 cycles of chemotherapy were considered chemotherapy sensitive. Among patients with tumors less sensitive to chemotherapy, sequential treatment with neoadjuvant endocrine therapy plus CDK4/6 inhibitors significantly improved ORR (61.8% vs 32.4%, P = .028) and was associated with greater Ki67 reduction and improved Miller-Payne grades.
Conclusion
Neoadjuvant endocrine therapy is a promising alternative for HR-positive breast cancer, especially for patients with poor responses to chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Zhang, M., Li, M., Zhou, S., Jiang, M., Liu, J., Yang, X., Qin, L., Abudureheiyimu, N., Shi, X., Li, L., Li, F., Guan, X., Ma, F., Xu, B., & Li, Q. (2026). Efficacy of neoadjuvant endocrine therapy with CDK4/6 inhibitors in locally advanced breast cancer. The Oncologist, 31(3). https://doi.org/10.1093/oncolo/oyag032
Vancouver
Zhang M, Li M, Zhou S, Jiang M, Liu J, Yang X, et al. Efficacy of neoadjuvant endocrine therapy with CDK4/6 inhibitors in locally advanced breast cancer. The Oncologist. 2026;31(3). doi:10.1093/oncolo/oyag032
BibTeX
@article{Zhang2026,
author = {Zhang, Mengqi and Li, Mingxiao and Zhou, Shihan and Jiang, Mingxia and Liu, Jiaxuan and Yang, Xue and Qin, Ling and Abudureheiyimu, Nilupai and Shi, Xiuqing and Li, Lixi and Li, Fengjuan and Guan, Xiuwen and Ma, Fei and Xu, Binghe and Li, Qiao},
title = {Efficacy of neoadjuvant endocrine therapy with CDK4/6 inhibitors in locally advanced breast cancer},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {3},
doi = {10.1093/oncolo/oyag032}
}
EUVIMED